Dfn-15

Malignant Peritoneal Mesothelioma

David BartlettPhase 1/2Dormant

CCC

52/ 100

Provisional rating · Methodology v0.2

Rating breakdown

4 Active assets in the Malignant Peritoneal Mesothelioma cohort.

Asset / Sponsor	Phase	Rating
Atezolizumab M.D. Anderson Cancer Center	Phase 2	CCC
INTERFERON ALFA-2B David Bartlett	Phase 1/2	CCC
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI)	Phase 1/2	CCC
trc102 National Cancer Institute (NCI)	Phase 1/2	CCC
IMMUNOGLOBULIN G1, ANTI-(HUMAN MESOTHELIN) (HUMAN MONOCLONAL MF-T-IGG1 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL MF-T-IGG1 .LAMBDA.-CHAIN, DIMER, N6-(4-((4-(3-(BIS(2-(((1,2-DIHYDRO-3-(HYDROXY-.KAPPA.O)-1-METHYL-2-(OXO-.KAPPA.O)-4-PYRIDINYL)CARBONYL)AMINO)ETHYL)AMINO)-2-((BIS(2-(((1,2-DIHYDRO-3-(HYDROXY-.KAPPA.O)-1-METHYL-2-(OXO-.KAPPA.O)-4-PYRIDINYL)CARBONYL)AMINO)ETHYL)AMINO)METHYL)PROPYL)PHENYL)AMINO)-1,4-DIOXOBUTYL)-L-LYSINE COMPLEX WITH THORIUM-227TH Bayer	Phase 1	CC
Rintatolimod David Bartlett	Phase 1/2	CC
Pegargiminase Polaris Group	Phase 1	CC
ct-95 Context Therapeutics Inc.	Phase 1	CC